Research programme: mitochondrial protein modulators - Metabolic Solutions Development Company
Latest Information Update: 16 Jul 2016
At a glance
- Originator Metabolic Solutions Development Company
- Class Small molecules
- Mechanism of Action Mitochondrial protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer; Inflammation; Neurodegenerative disorders; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Type-2-diabetes-mellitus in USA (PO)
- 02 Oct 2012 Pharmacodynamics data from a preclinical trial in Type-2 diabetes mellitus presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD-2012)
- 13 Jun 2012 Early research in Type-2 diabetes mellitus in USA (PO)